Our Products

Oral Fluid Convenience
Non-invasive collection process that can be administered quickly virtually anytime or anywhere. High quality saliva collection alternative to Quantisal® by Immunalysis.

Comprehensive Screen
Enables accurate testing for drugs of abuse, including marijuana, cocaine, PCP, opiates, and amphetamines – including Ecstasy (All included on standard panel). Intercept can also be used to screen for Barbiturates, Benzodiazepines and Methadone. Your laboratory can set up drug combinations that work for your testing program.

Reduced Tampering
Enables direct observation during collection process, which drastically reduces the opportunity for tampering and use of adulteration products.

Elimination of Gender Issues
Offers non-invasive, oral fluid testing, which can be administered in any location, eliminating the need for private bathrooms and same-sex test administrators.

Laboratory Confidence
Delivers proven laboratory reliability and accuracy comparable to urine testing.

The CareStart™ COVID-19 Antigen Home Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigens from SARS-CoV-2. Under FDA’s EUA, CareStart™ COVID-19 Antigen Home Test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years or older with symptoms of COVID-19 within the first 7 days of symptom onset. This test is also authorized for non-prescription home use with adult-collected nasal (nares) swab samples from individuals aged 2 years or older with symptoms of COVID-19 within the first 7 days of symptom onset. This test is also authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years or older, or adult-collected anterior nasal (nares) swab samples from individuals aged 2 years or older, with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests

OraSure has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its COVID-19 rapid antigen tests, which the Company is branding as InteliSwab™. The FDA has authorized the InteliSwab™ COVID-19 Rapid Test for Over-the-Counter (OTC) use without a prescription. FDA has also authorized the InteliSwab™ COVID-19 Rapid Test Pro for professional use in point of care (POC) CLIA-waived settings, and InteliSwab™ COVID-19 Rapid Test Rx for Prescription Home Use. These remarkably simple COVID-19 lateral flow tests use samples self-collected from the lower nostrils. InteliSwab’s unique design incorporates a built-in swab fully integrated into the test stick. After users swab their lower nostrils, the test stick is swirled in a pre-measured buffer solution, and the result appears right on the test stick within 30 minutes, with no instruments, batteries, smartphone or laboratory analysis needed to see the result.

• Protection from unwanted or dangerous substances
• Beaded cuff makes donning easy and helps prevent roll back
• Superior strength with better puncture resistance
• Full textured enhances wet and dry grip
• Thinner gauger improves tactile sensitivity
• Custom design enhances comfort and fit
• Provide an alternative solution for individuals who are allergic to natural rubber latex

• 510K-Certified Anti-fentanyl and chemo tested glove
• Protection from unwanted or dangerous substances
• Beaded cuff makes donning easy and helps prevent roll back
• Superior strength with better puncture resistance
• Full textured enhances wet and dry grip
• Thinner gauger improves tactile sensitivity
• Custom design enhances comfort and fit
• Provide an alternative solution for individuals who are allergic to natural rubber latex